IRESSA (gefitinib, ZD1839) – AstraZeneca Oncology

Where is gefitinib available?

Gefitinib (IRESSA) is currently approved for use in advanced NSCLC in the following countries.

Argentina
Australia
Bahrain
Canada*
Chile
China
Curacao
Dominican Republic
El Salvador
Guatemala
Honduras
Hong Kong
India
Indonesia
Israel
Japan
South Korea
Malaysia
Mexico
New Zealand
Nicaragua
Panama
Peru
Qatar
Russia
The Philippines
Serbia & Montenegro
Singapore
Sri Lanka
Switzerland*
Taiwan
Thailand
United Arab Emirates
Uruguay
USA*
Venezuela

*Please note that the use of gefitinib is restricted in the United States, Canada and Switzerland. For further information, please contact your health care professional.

Search

Site services